Risk Factors for Pneumocystis jirovecii Pneumonia in Patients With Lymphoproliferative Disorders

Micro-Abstract We conducted a retrospective, case-control study to identify risk factors associated with Pneumocystis jirovecii pneumonia (PCP) in patients with hematologic malignancies. All identified cases (n = 14) had lymphoproliferative disorders; they were matched with 56 controls. Fludarabine...

Full description

Saved in:
Bibliographic Details
Published inClinical lymphoma, myeloma and leukemia Vol. 12; no. 1; pp. 66 - 69
Main Authors Obeid, Karam M, Aguilar, Javier, Szpunar, Susan, Sharma, Mamta, del Busto, Ramon, Al-Katib, Ayad, Johnson, Leonard B
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.02.2012
Subjects
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Autoimmune diseases
Case-Control Studies
Chemotherapy
Cladribine - therapeutic use
Female
Fludarabine
Hematology, Oncology and Palliative Medicine
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - complications
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Lymphoma, Non-Hodgkin - complications
Lymphoma, Non-Hodgkin - drug therapy
Lymphoproliferative disorders
Lymphoproliferative Disorders - complications
Lymphoproliferative Disorders - drug therapy
Male
Middle Aged
Pneumocystis carinii - drug effects
Pneumonia, Pneumocystis - complications
Pneumonia, Pneumocystis - diagnosis
Pneumonia, Pneumocystis - prevention & control
Primary prophylaxis
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use
Vidarabine - analogs & derivatives
Vidarabine - therapeutic use
Primary prophylaxis
Chemotherapy
Fludarabine
Lymphoproliferative disorders
Autoimmune diseases
Online AccessGet full text

Cover

More Information
Summary:Micro-Abstract We conducted a retrospective, case-control study to identify risk factors associated with Pneumocystis jirovecii pneumonia (PCP) in patients with hematologic malignancies. All identified cases (n = 14) had lymphoproliferative disorders; they were matched with 56 controls. Fludarabine use and autoimmune diseases were found to be associated with PCP. Primary PCP prophylaxis should be considered for patients with lymphoproliferative malignancies and autoimmune diseases who are receiving fludarabine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2011.07.006